Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia
Urinary ascorbyl peroxide level in the first week of life will be a good predictor of Bronchopulmonary dysplasia (BPD) in preterm infants less than 33 weeks of gestation.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Urinary Ascorbyl Peroxide as an Early Biological Marker of Bronchopulmonary Dysplasia in Preterm Infants Less Than 33 Weeks of Gestation|
- Bronchopulmonary Dysplasia [ Time Frame: 4 Months ] [ Designated as safety issue: No ]To correlate the level of urinary Ascobyl peroxide and BPD. Full diagnosis and classification (to mild, moderate or severe) is at 36 weeks of corrected age; so even for most premature infants (like 23 weeks of gestation) there will be a need for follow up for less than 4 month to have the final diagnosis at 36 weeks
- The redox status (in blood) [ Time Frame: First week of life (week 1) ] [ Designated as safety issue: No ]Testing the correlation between the urinary level of ascorbyl peroxide and the redox status in the blood at 5 to 7 days of life
- Major neonatal outcomes (NEC, ROP, PDA, IVH, PVL) [ Time Frame: 4 Months ] [ Designated as safety issue: No ]These outcomes are the major neonatal outcomes for preterm infants, we would test the correlation between ascorbyl peroxide (as marker of oxidative stress) and like Necrotising entercolotis (NEC), Retinopathy of prematurity (ROP),patent dusctus arteriosus(PDA), intraventricular hemorrhage (IVH) and periventricular leucomalacie (PVL).
Biospecimen Retention: Samples With DNA
Urine sample (650 µl) Blood sample (500 µl)
|Study Start Date:||November 2011|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||November 2013 (Final data collection date for primary outcome measure)|
Preterm less than 33 weeks
This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
This study uses ascorbyl peroxide as representative of oxidative stress in premature infants on parenteral nutrition and aims to test the correlation of this metabolite and the different major neonatal outcomes 'mainly bronchopulmonary dysplasia).
|Contact: Ibrahim Mohamed, MB CHB||15143454931 ext email@example.com|
|Contact: Jean-Claude Lavoie, PhD||15143454931 ext firstname.lastname@example.org|
|University of Montreal, Sainte-Justine Hospital||Not yet recruiting|
|Montreal, Quebec, Canada, H3T1C5|
|Contact: Ibrahim Mohamed, MB ChB 15143454931 ext 4441 email@example.com|
|Principal Investigator: Ibrahim Mohamed, MB ChB|
|Principal Investigator: Jean-Claude Lavoie, PhD|
|Sub-Investigator: Anne-Monique Nuyt, MD|
|Principal Investigator:||Ibrahim Mohamed, Mb CHB||University of Montreal, Sainte Justine Hospital|
|Study Director:||Jean-claude Lavoie, PhD||University of Montreal, Sainte-Justine hospital research center|